Fortis Healthcare shares slid 1.9% on NSE after the government announced a 30% cap on trade margins for all non‑scheduled anti‑cancer drugs—marking a sharp reaction that rattled the broader pharma‑hospital sector.
The cap trims the prevailing average markup of 170% (as high as 700%) on these drugs, a move that could slash prices by up to 70% in some cases and generate roughly ₹2,500 crore in annual savings for patients, according to the National Pharmaceutical Pricing Authority. With an estimated ₹12,500 crore turnover across 225 drugs and 500 formulations, the policy touches a sizable slice of the oncology market.
Hospital chains, however, are insulated to a large extent. Oncology drugs comprise less than 5% of total revenue and only 2‑2.5% of EBITDA for most multi‑specialty groups, Goldman Sachs told analysts. Even under a bearish scenario, the firm estimates an EBITDA hit of under 2%, a figure that explains the limited downward pressure on the likes of Max Healthcare and Fortis.
Pharmaceutical makers face a more ambiguous future. While the cap targets trade margins and not manufacturer prices, some firms may feel compelled to cut prices if their margins tighten. The 12‑October court hearing will decide whether the new pricing framework triggers wider regulatory shifts, a point that has already injected caution into the market.
Looking ahead, investors will be watching the October 12 hearing and the committee’s January 2027 recommendations for any sign of tighter controls. In the short term, volatility is likely to persist as traders recalibrate valuations in light of the new margin cap and its potential ripple effects across the pharma‑hospital chain.